Kato R, Kamatari T (eds).

[Drug Metabolism] (In Japanese)

Tokyo Kagaku Dojin (2000)

Gjerde J, Kisanga ER, Hauglid M, Holm PI, Mellgren G, Lien EA.

Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry.

J Chromatogr A 1082:6-14 (2005)
DOI:10.1016/j.chroma.2005.01.004

Buck MB, Coller JK, Murdter TE, Eichelbaum M, Knabbe C.

TGFbeta2 and TbetaRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells.

Breast Cancer Res Treat 107:15-24 (2008)
DOI:10.1007/s10549-007-9526-7

Rodriguez-Antona C, Ingelman-Sundberg M.

Cytochrome P450 pharmacogenetics and cancer.

Oncogene 25:1679-91 (2006)
DOI:10.1038/sj.onc.1209377

Zhang J, Tian Q, Yung Chan S, Chuen Li S, Zhou S, Duan W, Zhu YZ.

Metabolism and transport of oxazaphosphorines and the clinical implications.

Drug Metab Rev 37:611-703 (2005)
DOI:10.1080/03602530500364023

Kosel M, Amey M, Aubert AC, Baumann P.

In vitro metabolism of citalopram by monoamine oxidase B in human blood.

Eur Neuropsychopharmacol 11:75-8 (2001)
DOI:10.1016/S0924-977X(00)00128-0

Olesen OV, Linnet K.

Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes.

Pharmacology 59:298-309 (1999)
DOI:10.1159/000028333

Rochat B, Kosel M, Boss G, Testa B, Gillet M, Baumann P.

Stereoselective biotransformation of the selective serotonin reuptake inhibitor citalopram and its demethylated metabolites by monoamine oxidases in human liver.

Biochem Pharmacol 56:15-23 (1998)
DOI:10.1016/S0006-2952(98)00008-2

David AW, Thomas LL, William OF.

Foye's Principles of Medicinal Chemistry (5th ed)

Lippincott Williams & Wilkins (2002)

Oda Y, Kharasch ED.

Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation.

J Pharmacol Exp Ther 298:1021-32 (2001)

Wang JS, Backman JT, Taavitsainen P, Neuvonen PJ, Kivisto KT.

Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans.

Drug Metab Dispos 28:959-65 (2000)

Dieckhaus CM, Thompson CD, Roller SG, Macdonald TL.

Mechanisms of idiosyncratic drug reactions: the case of felbamate.

Chem Biol Interact 142:99-117 (2002)
DOI:10.1016/S0009-2797(02)00057-1

Pearce RE, Lu W, Wang Y, Uetrecht JP, Correia MA, Leeder JS

Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine.

Drug Metab Dispos 36:1637-49 (2008)
DOI:10.1124/dmd.107.019562

Pearce RE, Vakkalagadda GR, Leeder JS.

Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites.

Drug Metab Dispos 30:1170-9 (2002)
DOI:10.1124/dmd.30.11.1170

Kumar S, Wong H, Yeung SA, Riggs KW, Abbott FS, Rurak DW.

Disposition of valproic acid in maternal, fetal, and newborn sheep. II: metabolism and renal elimination.

Drug Metab Dispos 28:857-64 (2000)

Bernad T, Joachim M.

Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology

Wiley-VCH (2003)